| |
PolyMedix focuses on developing novel high-value therapeutic drug products for serious, life-threatening acute disorders. We attack these challenges with biomimetics - novel small molecule compounds and polymers which mimic the activity of proteins. These compounds are designed with a proprietary computational technology platform which focuses on a specific field of biology with many potential product opportunities: membrane:protein and protein:protein interactions.
PolyMedix focuses on serious, life threatening, acute disorders which are also significant market opportunities. Using our proprietary computational drug design technology, we have created novel antibiotic compounds and heptagonists. Our lead candidates in each of these programs, i.v. antibiotic candidate PMX-30063 and the anticoagulant antagonist product candidate PMX-60056, are
currently in human clinical trials.
PMX-30063 began phase I clinical
trials in August, 2008 and PMX-60056
began clinical trials in September
2008.
PolyMedix is a publicly traded company (OTC BB:PYMX).
November 07, 2008
PolyMedix’s CEO to Present at Rodman & Renshaw’s Tenth Annual Global Healthcare Conference on November 10, 2008
Radnor, PA (November 7, 2008) - PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, will present at Rodman & Renshaw’s Tenth Annual Global Healthcare Conference taking place November 10-12, 2008, at the New York Palace Hotel. Nicholas Landekic, President & C.E.O. of PolyMedix, will give the Company presentation on Monday, November 10 at 5:45 PM (EST) in the Louis Room. »read more
|
|
|
October 28, 2008
POLYMEDIX TO MAKE MULTIPLE PRESENTATIONS OF NEW ANTIBIOTIC DATA AT THE 48th ANNUAL INTERSCIENCE CONFERENCE ON ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (ICAAC)
Annual Meeting on Behalf of the American Society of Microbiology (ASM) Being Held In Washington D.C., October 25 - 28, 2008
Data to be presented include new data for PolyMedix antibiotic compounds that have demonstrated antimalarial activity and antifungal activity, as well as in vitro and in vivo Staphylococci data on PolyMedix’s Phase I i.v. antibiotic product candidate, PMX-30063
Radnor, PA (October 28, 2008) -PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, will make a total of four presentations of pre-clinical data on its antibiotic compounds at the Interscience Conference on Antimicrobial Agents and Chemotherapy. The conference, held on behalf of the American Society for Microbiology (ASM) and the Infectious Diseases Society of America (IDSA), is taking place in Washington D.C. Saturday, October 25 through Tuesday, October 28, 2008. »read more
|
|
